

Form PTO-1595

(Rev. 03-01)

OMB No. 0651-0027 (exp. 5/31/2002)

Tab settings ▼

To the Honorable Commissi

05-02-2002



1000

U.S. Department of Commerce  
U.S. Patent and Trademark Office

1. Name of conveying party(ies):

Inex Pharmaceuticals Corporation

102075140

e attached original documents or copy thereof

address of receiving party(ies)

Additional name(s) of conveying parties attached? ☐ Yes ☒ No.

3. Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other: \_\_\_\_\_

Name: Protiva Biotherapeutics Inc.

Internal Address: 150-8900 Glenlyon Parkway

Street Address: Glenlyon Business Park

City: Burnaby State: B.C. ZIP: V5J 5J8

Additional names and addresses attached? ☐ Yes ☒ No

Execution Date: April 11, 2002

4. Application number(s) or patent number(s).

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

A. Patent Application No(s):  
09/295,663, 09/243,102, 09/295,925

B. Patent No(s):

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Carol Fang  
TOWNSEND AND TOWNSEND AND CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
(415) 576-0200

6. Total number of applications and patents involved 3

7. Total fee (37 CFR 3.41): -----\$120.00

☐ Enclosed☒ Authorized to be charged to deposit account

8. Deposit account number: 20-1430

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing is true and correct and any attached copy is a true of copy of the original document.*

Carol Fang

Name of Person Signing  
Atty. Reg. No. 48,631

Signature

Date

Total number of pages including cover sheet, attachments and document 3

Mail documents to be recorded with required cover to:  
Commissioner of Patents and Trademarks, Box Assignments  
Washington, D.C. 20231

05/01/2002 TDIAZ1 00000186 201430 09295663

01 FC:581 120.00 CH

PATENT  
REEL: 012840 FRAME: 0724

## ASSIGNMENT OF PATENT APPLICATION

WHEREAS, Inex Pharmaceuticals Corporation of 100-8900 Glenlyon Parkway, Glenlyon Business Park, Burnaby, B.C., Canada, V5J 5J8, hereinafter referred to as "Assignor," is the owner of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: COMBINATION THERAPY USING NUCLEIC ACIDS  
AND CONVENTIONAL DRUGS

Filing Date: April 21, 1999

Application No.: 09/295,663;

and

Title of Invention: SYSTEMIC DELIVERY OF SERUM STABLE PLASMID  
LIPID PARTICLES FOR CANCER THERAPY

Filing Date: February 2, 1999;

Application No.: 09/243,102

and

Title of Invention: COMBINATION THERAPY USING NUCLEIC ACIDS  
AND RADIO THERAPY

Filing date: April 21, 1999

Application No.: 09/295,925; and

WHEREAS, Protiva Biotherapeutics Inc., of 150-8900 Glenlyon Parkway, Glenlyon Business Park, Burnaby, B.C., Canada, V5J 5J8, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignor, Assignor has assigned, and by these presents does assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignment

Attorney Docket Nos.: 20801-000720US;

000920US; 001010US


Page 2

Assignor further agrees that Assignor will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Dated: April 11, 2002

INEX Pharmaceuticals Corporation

By   
David Main, CEO and President

SIGNATURE WITNESSED BY:

(1) Dated: April 11, 2002

(2) Dated: April 11, 2002

